Obe-Cel Stands Out in ALL as the Sole FDA-Approved CAR T-Cell Therapy Given Via Split Dosing
Elias Jabbour, MD, highlights the significance of obecabtagene autoleucel’s approval for patients with B-cell precursor ALL and data from the FELIX trial.
Related Articles
Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma
A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.
Knowing your risk for inherited cancers matters
Testing for inherited cancer risk has become more accessible, affordable and accurate. Fred Hutch clinicians and researchers explain why it can be important, how to…
The use of wearable technology in studies in older adults with cancer: a systematic review
AbstractBackground. Despite the increasing integration of wearable technology in oncology, its application in the care of older adults, representing most p
Phase 3 lung cancer trial misses survival endpoint
A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of…
Three‐dimensional printing technology: A novel tool in guiding surgical management of retroperitoneal sarcoma
Retroperitoneal sarcoma is a complex entity that requires specialized surgical management. Three-dimensional printing technology may represent a valuable adjunctive tool for the preoperative assessme…
Video Highlights
Brief Messsage from Dr. Virginia Kaklamani, MD Stay informed with daily video updates on the most significant science presented at SABCS® 2024. Watch top global…
FDA Receives BLA for RP1 and Nivolumab Combo in Advanced Melanoma
The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 inhibitor–exposed melanoma.
Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment & multidisciplinary care | VJHemOnc
A session filmed virtually featuring leading experts Marlise Luskin, Nicole LeBoeuf, and Shai Shimony, who discuss the clinical presentation, diagnosis, and treatment of blastic plasmacytoid…
Editors’ Selections from Relevant Scientific Publications
Physical activity delays PDAC development (by Pita-Grisanti et al via Cancer Research)A new study investigated the impact of physical activity on inflammation and the development…
CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression
Integrative analysis of eRNA-producing super-enhancers defines molecular mechanisms controlling global patterns of gene expression that regulate clinical outcomes in breast cancer, highlighting the potential of…
